Alan J. Arville, Member of the Firm, will co-present “The Drug Cost Controversy, Part 2: What’s Next?” at the APhA2020 Annual Meeting & Exposition, which runs from March 20 to 23.
Federal and state leaders are pursuing ways to reform drug pricing and reimbursement amid competing ideas and pressure from patients across the country. Presenters will outline trends and events—along with legal reforms currently on the table—predicted to inform pricing in 2020 and beyond.
- Trends and themes in drug pricing and reimbursement policy, including federal and state initiatives to address PBM rebates, PBM gag clauses, manufacturer price increases, and transparency
- Medicare Part B and D developments, including the International Index Pricing Model; and Medicaid, including state waivers for outcome-based contracts
- Regulatory hurdles for value-based contracting for pharmaceuticals
For more information, visit APhAMeeting.com.